RBPJL and neoplasm: Compared with IgG, toripalimab significantly increased tumor‐infiltrating CD4+ and CD8+ T cells and inhibited tumor cell proliferation, as indicated by the downregulation of Ki67 expression, while the RBPJL‐overexpressing group showed more infiltration in the presence of toripalimab.